Skip to content
Medical Health Aged Care, Science

Opioid and psychotropic dispensing’s on the decline among Australians living with cystic fibrosis

Monash University 2 mins read
Cystic fibrosis

For the first time in Australia, Monash University researchers have analysed national dispensing data to assess the impact ‘modulator therapy’ has had on Australians living with cystic fibrosis. 


In the context of cystic fibrosis, a modulator is a group of medicines intended to correct the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein by targeting the underlying cause of the disease. 


In this study, conducted by the Centre for Medicine Use and Safety (CMUS) within the Monash Institute of Pharmaceutical Sciences, the team found those using a modulator had less opioid and psychotropic medicines dispensed compared to those not using a modulator.


The researchers used a 10 per cent sample of Australian Pharmaceutical Benefits Scheme (PBS) data between 2013 and 2022. The data showed that after 7.5 years, patients using a modulator had decreased opioid use compared to their pre-modulator period, and use of psychotropic medicines remained stable (while those not on a modulator had an increase in psychotropics dispensing’s).


Not only do CFTR modulators improve or slow decline in respiratory function and reduce hospital admissions, but ongoing research demonstrates non-pulmonary improvements such as improved nutritional status and control of cystic fibrosis related-diabetes.


In 2014 the first CFTR modulator became available through the PBS, with several options now available to the majority of the approximately 3,500 Australians living with cystic fibrosis.


CMUS PhD candidate and Experiential Development and Graduate Education (EDGE) Senior Lecturer (Practice),
Louise Lord, said studies specifically investigating the impact of modulators on other medication use are rare.


“This is the first real-world analysis of Australian pharmaceutical dispensing data in people living with cystic fibrosis initiated on a CFTR modulator,” Ms Lord said.


“The study has highlighted previously unrecognised changes in medication dispensing's outside the usual focus of antimicrobial, mucolytic and insulin therapies and identified novel findings of decreased opioid and psychotropic dispensing's in those initiated on a modulator.”


Dr Jenni Ilomaki, a CMUS Senior Lecturer and senior author of the study said: “These findings are important because by improving our understanding of how medication use has altered after modulator initiation, it may also provide opportunities to further optimise treatment regimens and decrease burden.”


The study is published in the journal
Pulmonary Pharmacology and Therapeutics.


Other authors include CMUS PhD candidate Miriam Leung, CMUS Research Fellow Dr Jed Morton and Adjunct Clinical Professor Mark Hew from Monash University’s
School of Public Health and Preventive Medicine.


ENDS


https://doi.org/10.1016/j.pupt.2023.102264


Contact details:

Kate Carthew

+61 438 674 814

kate.carthew@monash.edu 

Media

More from this category

  • Environment, Science
  • 12/07/2024
  • 13:20
The ARC Centre of Excellence for Climate Extremes

Study reveals how climate patterns contribute to coral bleaching in the Great Barrier Reef

A new study finds a significant impact of the Madden-Julian Oscillation (MJO) and El Niño Southern Oscillation (ENSO) on coral bleaching events in the Great Barrier Reef (GBR). The GBR, covering almost 350,000 square kilometres along Australia's northeastern coast, is the world's largest coral ecosystem. Renowned for its biodiversity, cultural significance, and economic value, it contributes around $6.4 billion annually to the Australian economy. However, it faces serious threats from increasing ocean temperatures due to climate change. A new paper, Combined Role of the MJO and ENSO in Shaping Extreme Warming Patterns and Coral Bleaching Risk in the Great Barrier…

  • Contains:
  • Government NSW, Medical Health Aged Care
  • 12/07/2024
  • 12:39
MEDIA RELEASE - Network of Alcohol & Other Drug Agencies

NSW DRUG SUMMIT IS AN OPPORTUNITY TO SHELVE OUTDATED POLICIES

12 July 2024 The forthcoming NSW Drug Summit is an opportunity to shelve outdated drug policies that have failed to deliver better health andwellbeing outcomes for individuals and their families. That’s the verdict from the peak organisation for the non-government drug and alcohol sector in NSW, the Network of Alcohol and other Drugs Agencies (NADA). NADA today welcomed the Government’s confirmation the NSW Drug Summit will be held over two days in regional NSW in October, and in Sydney on 4th and 5th December, as well as consultations about the Terms of Reference and other matters ahead of this. NADA…

  • Contains:
  • Science
  • 12/07/2024
  • 09:50
Monash University

Off balance: New studies unravel the climate pattern impacts on the Antarctic Ice Sheet

The Southern Annular Mode andEl Niño-Southern Oscillation are causing large year-to-year variations in Antarctic snow accumulation and surface melt. Findings from two new research papers are supporting efforts to predict how Antarctica will respond to future climate change. Change in the Antarctic creates ripple effects all over the planet, including sea level rise and shifts in weather patterns. New Monash research has untangled the influence of regional climate drivers, including the Southern Annular Mode (SAM) and the El Niño-Southern Oscillation (El Niño), on the Antarctic Ice Sheet. Snow accumulation and surface melting are two important processes that are key to…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.